Generics BulletinTwo companies of similar economic scale and each with its own troubled financial history revealed plans to merge on 13 March, as privately held Mallinckrodt and publicly traded Endo will combine into
ScripTwo companies of similar economic scale and each with its own troubled financial history revealed plans to merge on 13 March, as privately held Mallinckrodt and publicly traded Endo will combine into
Generics BulletinMallinckrodt says it is “more than happy” to continue executing on only two or three generic controlled-substance launches per year in the US, as the firm looks to maintain and grow its operations 12
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Crown Will Offer $924m To Merge With Re